Correlation between MRI and short-term clinical activity in multiple sclerosis: Comparison between standard- and triple-dose Gd-enhanced MRI

European Neurology

Volumn 41, Issue 3, 1999, Pages 123-127

  Rovaris, M ^a   Rodegher, M ^a   Comi, G ^a   Filippi, Massimo ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Disease activity; Gadolinium DTPA; Magnetic resonance imaging; Multiple sclerosis

Indexed keywords

GADOLINIUM; GADOLINIUM PENTETATE; STEROID;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN SCINTISCANNING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; STEROID THERAPY;

EID: 0032916502     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000008034     Document Type: Article

References (22)

1. Miller DH, Barkhof F, Nauta JJP: Gadolinium enhancement increased the sensitivity of MRI in detecting disease activity in MS. Brain 1993; 116:1077-1094.
2. Filippi M, Miller DH: MRI in the differential diagnosis and monitoring the treatment of multiple sclerosis. Curr Opin Neurol 1996;9:176-186.
3. Kermode AG, Thompson AJ, Tofts P, MacManus DG, Kendall BE, Kingsley DPE, Moseley IF, Rudge P, McDonald WI: Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis: Pathogenetic and clinical implications. Brain 1990; 113:1477-1489.
4. Barkhof F, Scheltens P, Frequin STMF, Nauta JJ, Tas MW, Valk J, Hommes OR: Relapsing-remitting multiple sclerosis: Sequential enhanced MR imaging vs. clinical findings in determining disease activity. Am J Roentgenol 1992;159:1041-1047.
5. Smith ME, Stone LA, Albert PS, Frank JA, Martin R, Armstrong M, Maloni H, McFarlin DE, McFarland HF: Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 1993;33:480-489.
6. Thorpe JW, Kidd D, Moseley IF, Kendall BE, Thompson AJ, MacManus DG, McDonald WI, Miller DH: Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology 1996;46:373-378.
7. Gasperini C, Pozzilli C, Bastianello S, Koudriatseva T, Colleluori A, Millefiorini E, Thompson AJ, Horsfield MA, Galgani S, Bozzao L, Fieschi C: The influence of clinical relapses and steroid therapy on the development of Gd-enhancing lesions: A longitudinal MRI study in relapsing-remitting patients. Acta Neurol Scand 1997;95:201-207.
8. Filippi M, Yousry T, Campi A, Kandziora C, Colombo B, Voltz R, Martinelli V, Spuler S, Bressi S, Scotti G, Comi G: Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. Neurology 1996;46:379-384.
9. Metha RC, Pike BG, Enzmann DR: Improved detection of enhancing and nonenhancing lesions of multiple sclerosis with magnetization transfer. Am J Neuroradiol (AJNR) 1995;16: 1771-1778.
10. Silver NC, Good CD, Barker GJ, MacManus DG, Thompson AJ, Moseley IF, McDonald WI, Miller DH: Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain 1997;120: 1149-1161.
11. Lai M, Hodgson T, Gawne-Cain M, Webb S, MacManus DG, McDonald WI, Thompson AJ, Miller DH: A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis. J Neurol Neurosurg Psychiatry 1996; 60:339-341.
12. McDonald WI, Miller DH, Barnes D: The pathological evolution of multiple sclerosis. Neuropathol Appl Neurobiol 1992;18:319-334.
13. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW: New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983;13:227-231.
14. Filippi M, Rovaris M, Capra R, Gasperini C, Yousry TA, Sormani MP, Prandini F, Horsfield MA, Martinelli V, Bastianello S, Kuhne I, Pozzilli C, Comi G: A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis: Implications for clinical trials. Brain 1998;121:2011-2020.
15. Kurtzke JF: Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
16. Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ: Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: Concerted Action Guidelines. J Neurol Neurosurg Psychiatry 1991;54:683-688.
17. Rovaris M, Filippi M, Calori G, Rodegher M, Campi A, Colombo B, Comi G: Intra-observer reproducibility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: A comparison with T2-weighted images. J Neurol 1997;244:266-270.
18. Tofts PS, Kermode AG: Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. I. Fundamental concepts. Magn Reson Med 1991;17: 357-367.
19. Filippi M, Rocca MA, Rizzo G, Horsfield MA, Rovaris M, Minicucci L, Colombo B, Comi G: Magnetization transfer ratios in MS lesions enhancing after different doses of gadolinium-DTPA. Neurology 1998;50:1289-1293.
20. Barkhof F, Hommes OR, Scheltens P, Valk J: Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology 1991;41:1219-1222.
21. Miller DH, Thompson AJ, Morrissey SP, MacManus DG, Moore SG, Kendall BE, Moseley IF, McDonald WI: High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 1992;55:450-453.
22. Filippi M, Rovaris M, Capra R, Gasperini C, Martinelli V, Sormani MP, Bastianello S, Comi G: Serial standard- and triple-dose MRI to monitor the effect of interferon β-1a on multiple sclerosis activity. Neurology 1998;50(S4): A323.